



DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

Date: October 19, 2022	Time: 10:00am – 3:00pm (CST)	Location: Howerton State Office Building Conference Room 202 Jefferson City, MO 65109
----------------------------------	--	---

Additional Meeting Details

The June 16th DPAC meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**.

Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2452 869 6537
Meeting password: XQi4jvNp7P7

<p><u>Join from a Video System/Application</u> Dial 24528696537 @stateofmo.webex.com Or dial 173.243.2.68 and enter the meeting number</p>	<p><u>Join from a Mobile Device (attendees only)</u> 1-650-479-3207 Call-in toll number (US/Canada)</p>
--	---

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates		
10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
Old Business		
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA’s	Josh Moore
New Business		
10:45 – 11:00	Proposed Actions – New Drug/Product Review (See Website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Agents iv. Prior Authorization	Olivia Rush
Clinical and Fiscal Edit Review		
11:00 – 11:45	<u>Existing Criteria</u> i. Entresto Clinical Edit ii. Spinal Muscular Atrophy (SMA) Clinical Edit	Josh Moore
	<u>New Criteria or Revision of Existing Criteria</u> i. Alpelisib Clinical Edit ii. Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit	

Preferred Drug List Edit Review

11:45 – 1:00

Existing Criteria

Josh Moore

- i. ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations PDL Edit
- ii. ACE-Inhibitors/Calcium Channel Blocker Combinations PDL Edit
- iii. ADHD, Methylphenidate, Short Acting PDL Edit
- iv. ADHD, Non-Stimulants PDL Edit
- v. Alpha-Glucosidase Inhibitors PDL Edit
- vi. Amylin Analogs PDL Edit
- vii. Antibiotics, Mupirocin Topical PDL Edit
- viii. Antihyperuricemic Agents PDL Edit
- ix. ARBs and ARBs/Diuretic Combinations PDL Edit
- x. ARBs/Calcium Channel Blocker Combinations PDL Edit
- xi. Benign Prostatic Hyperplasia (BPH) Agents PDL Edit
- xii. Beta Blockers & Beta Blockers/Diuretic Combinations PDL Edit
- xiii. Biguanides & Combinations PDL Edit
- xiv. Bone Ossification Agents PDL Edit
- xv. Calcium Channel Blockers, Non-Dihydropyridines PDL Edit
- xvi. Cephalosporin Agents PDL Edit
- xvii. Direct Renin Inhibitors & Combinations PDL Edit
- xviii. DPP-IV Inhibitors & Combinations PDL Edit
- xix. Electrolyte Depleting Agents, Phosphate Lowering PDL Edit
- xx. Fluoroquinolone Agents, Oral PDL Edit
- xxi. Homozygous Familial Hypercholesterolemia (HoFH) Agents PDL Edit
- xxii. Insulin, Mixed PDL Edit
- xxiii. Insulin, Non-Analogs PDL Edit
- xxiv. Insulin, Rapid Acting PDL Edit
- xxv. Macrolides PDL Edit
- xxvi. Meglitinides PDL Edit
- xxvii. Methotrexate Agents PDL Edit
- xxviii. Niacin Derivatives PDL Edit
- xxix. Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRA) PDL Edit
- xxx. Pulmonary Arterial Hypertension (PAH) Agents, PDE5-Inhibitors and SGC Stimulators PDL Edit
- xxxi. Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Oral PDL Edit
- xxxii. Penicillin Agents PDL Edit
- xxxiii. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents PDL Edit
- xxxiv. Statins (HMG-CoA Reductase Inhibitors) & Combinations PDL Edit
- xxxv. Sulfonylureas, Second Generation PDL Edit
- xxxvi. Tetracycline Agents PDL Edit
- xxxvii. Thiazolidinediones & Combinations PDL Edit
- xxxviii. Thrombocytopenia Agents PDL Edit
- xxxix. Triglyceride Lowering Agents PDL Edit

New Criteria or Revision of Existing Criteria

- i. ADHD, Amphetamines Long Acting PDL Edit
- ii. ADHD, Amphetamines, Short Acting PDL Edit
- iii. ADHD, Methylphenidate Long Acting PDL Edit
- iv. Antibiotics, GI Oral PDL Edit
- v. Antibiotics, Vaginal PDL Edit
- vi. Anticoagulants PDL Edit
- vii. Anticonvulsants, Rescue Agents PDL Edit

- viii. Bile Salt Agents PDL Edit
- ix. Calcium Channel Blockers, Dihydropyridines PDL Edit
- x. Colony Stimulating Factors PDL Edit
- xi. Cryopyrin-Associated Periodic Syndrome (CAPS) Agents PDL Edit
- xii. Dry Eye Disease Agents PDL Edit
- xiii. Electrolyte Depleting Agents, Potassium Lowering PDL Edit
- xiv. Erythropoiesis Stimulating Agents PDL Edit
- xv. Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists & Combination Agents PDL Edit
- xvi. Growth Hormone Agents, Somatropin PDL Edit
- xvii. Growth Hormone & Growth Hormone Releasing Factors, Select Agents PDL Edit
- xviii. Insulin, Long Acting PDL Edit
- xix. Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Edit
- xx. Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Oral PDL Edit
- xxi. Multiple Sclerosis Agents, Injectable PDL Edit
- xxii. Multiple Sclerosis Agents, Oral PDL Edit
- xxiii. Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Binders PDL Edit
- xxiv. Proton Pump Inhibitors PDL Edit
- xxv. Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Inhaled PDL Edit
- xxvi. Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Injectable PDL Edit
- xxvii. Sympatholytic Agents PDL Edit
- xxviii. Targeted Immune Modulators, IL17 Antibody/IL17 Receptor Antagonists PDL Edit
- xxix. Targeted Immune Modulators, IL23 Inhibitors and IL23/IL12 Inhibitors PDL Edit
- xxx. Targeted Immune Modulators, IL6 Receptor Inhibitors PDL Edit
- xxxi. Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit
- xxxii. Targeted Immune Modulators, Misc. Allergy and Asthma Related Monoclonal Antibodies PDL Edit
- xxxiii. Targeted Immune Modulators, Select Agents PDL Edit
- xxxiv. Targeted Immune Modulators, TNF Inhibitors PDL Edit
- xxxv. Urinary Tract Antispasmodics PDL Edit

Break

1:00 – 1:15 Lunch

Program Utilization Information – Conduent Update

1:15 – 1:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

Other Business/Closing Comments

1:30 – 1:50 Other Business

Executive Session

2:00 – 3:00 Patient Profile Reviews

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, agenda may move more quickly.*

Next Meeting: January 18, 2023

Meeting location and attendance options subject to change

Howerton Building, Room 202
615 Howerton Court
Jefferson City, MO 65109
Public attendance may be limited

Webex

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*